Effect of Bifidobacterium Breve Supplementation on the Onset and Progression of Idiopathic Scoliosis

ConditionIdiopathic Scoliosis

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age6-15

SponsorSecond Affiliated Hospital of Wenzhou Medical University

About this trial

Researchers hypothesized that Bifidobacterium breve Supplement could reduce the progression rate of idiopathic scoliosis in children and potentially prevent the occurrence of new cases of scoliosis.

Eligibility criteria

Qualifiers

Age 6 to 15 years

Disqualifiers

Plans to relocate within the next 24 months

Trial design

Treatments tested in this trial

Bifidobacterium breve
Lifestyle Education

Treatment groups

100 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Second Affiliated Hospital of Wenzhou Medical University

Lead sponsor

Source ClinicalTrials.gov